AZT Plus Methotrexate in HIV-Related Non-Hodgkin's Lymphomas

AZT is a thymidine analogue useful in the treatment of AIDS. It has been demonstrated that this compound can possess a significant antineoplastic activity when combined with de novo thymidylate synthesis inhibitors, such as 5-fluorouracil (5FU) and methotrexate (MTX). Here we report a review of our...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 1998-06, Vol.30 (1-2), p.175-179
Main Authors: Tosi, Patrizia, Gherlinzoni, Filippo, Visani, Giuseppe, Coronado, Olga, Costigliola, Paolo, Mazzetti, Magda, Gritti, Francesco, Chiodo, Francesco
Format: Article
Language:English
Subjects:
Adult
AIDS
Anti-HIV Agents - therapeutic use
Antimetabolites, Antineoplastic - therapeutic use
AZT
Drug Therapy, Combination
Female
Human immunodeficiency virus 1
Humans
lymphoma
Lymphoma, AIDS-Related - drug therapy
Male
methotrexate
Methotrexate - therapeutic use
Middle Aged
Zidovudine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AZT is a thymidine analogue useful in the treatment of AIDS. It has been demonstrated that this compound can possess a significant antineoplastic activity when combined with de novo thymidylate synthesis inhibitors, such as 5-fluorouracil (5FU) and methotrexate (MTX). Here we report a review of our data concerning the efficacy and tolerance of the combination AZT + MTX in HIV-related non Hodgkin's lymphomas (NHL). Twenty-nine patients were treated, at weekly intervals, with three (patient 1 to 10) or six (patient 11 to 29) consecutive courses of MTX lg/m2 and increasing doses of oral AZT (2,4 and 6g/m2) with leucovorin rescue. Of 26 evaluable patients, a total (complete + partial) response rate of 77% was obtained. The median complete response duration was 16.8 months. There was one therapy-related death due to septic shock. Grade III-IV neutropenia was observed after 19% of the courses, but was prevented by G-CSF administration in 82/119 courses. Grade III-IV anemia was observed after 9% of the courses. In conclusion, the combination AZT + MTX was effective and well tolerated in our series of HIV-related NHL patients.
ISSN:1042-8194
1029-2403
DOI:10.3109/10428199809050940